Ji‐Min Zhu

2.3k total citations · 1 hit paper
58 papers, 1.7k citations indexed

About

Ji‐Min Zhu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Ji‐Min Zhu has authored 58 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 16 papers in Cancer Research and 10 papers in Oncology. Recurrent topics in Ji‐Min Zhu's work include Cancer-related molecular mechanisms research (10 papers), RNA modifications and cancer (10 papers) and MicroRNA in disease regulation (8 papers). Ji‐Min Zhu is often cited by papers focused on Cancer-related molecular mechanisms research (10 papers), RNA modifications and cancer (10 papers) and MicroRNA in disease regulation (8 papers). Ji‐Min Zhu collaborates with scholars based in China, United States and Germany. Ji‐Min Zhu's co-authors include Xizhong Shen, Taotao Liu, Ling Dong, Shu‐Qiang Weng, Xiang‐Nan Yu, Guangcong Zhang, Guangqi Song, Danying Zhang, Hairong Zhu and Jie Yin and has published in prestigious journals such as Cell, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Ji‐Min Zhu

58 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gut-liver axis calibrates intestinal stem cell fitness

2024 42 citations Jialei Sun, Ji‐Min Zhu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ji‐Min Zhu China	25	1.0k	562	262	235	179	58	1.7k
Liang Chu China	27	1.5k 1.4×	638 1.1×	385 1.5×	112 0.5×	118 0.7×	65	2.2k
Xiaotong Hu China	24	1.0k 1.0×	416 0.7×	248 0.9×	151 0.6×	117 0.7×	82	1.7k
Zhengxiang Zhang China	21	1.1k 1.0×	558 1.0×	320 1.2×	134 0.6×	242 1.4×	46	1.8k
Weizhong Tang China	22	634 0.6×	297 0.5×	381 1.5×	230 1.0×	233 1.3×	105	1.5k
Yang Xu China	24	812 0.8×	449 0.8×	282 1.1×	349 1.5×	84 0.5×	87	1.7k
Francisco Dası́ Spain	21	1.0k 1.0×	287 0.5×	199 0.8×	162 0.7×	76 0.4×	62	1.8k
Xinyu Huang China	26	1.5k 1.4×	1.0k 1.8×	421 1.6×	211 0.9×	149 0.8×	70	2.3k

Countries citing papers authored by Ji‐Min Zhu

Since Specialization

Citations

This map shows the geographic impact of Ji‐Min Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ji‐Min Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ji‐Min Zhu more than expected).

Fields of papers citing papers by Ji‐Min Zhu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ji‐Min Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ji‐Min Zhu. The network helps show where Ji‐Min Zhu may publish in the future.

Co-authorship network of co-authors of Ji‐Min Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Ji‐Min Zhu. A scholar is included among the top collaborators of Ji‐Min Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ji‐Min Zhu. Ji‐Min Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Fu, Haoyu You, Huahua Liu, et al.. (2025). Silencing PTPN2 with nanoparticle-delivered small interfering RNA remodels tumor microenvironment to sensitize immunotherapy in hepatocellular carcinoma. Acta Pharmaceutica Sinica B. 15(6). 2915–2929. 3 indexed citations

Zhu, Ji‐Min, et al.. (2024). HuR facilitates miR-93-5p-induced activation of MAP3K2 translation via MAP3K2 3′UTR ARE2 in hepatocellular carcinoma. Biochemical and Biophysical Research Communications. 722. 150152–150152. 3 indexed citations

Zhang, Guangcong, Kang Song, Jun Du, et al.. (2024). Bismuth-based mesoporous nanoball carrying sorafenib for synergistic photothermal and molecularly-targeted therapy in an orthotopic hepatocellular carcinoma xenograft mouse model. Colloids and Surfaces B Biointerfaces. 245. 114279–114279. 2 indexed citations

Zhang, Danying, et al.. (2024). Clinical applications and perspectives of circulating tumor DNA in gastric cancer. Cancer Cell International. 24(1). 13–13. 14 indexed citations

Liu, Zhiyong, Guobo Chen, Xiang Wang, et al.. (2023). Synergistic Photochemo Effects Based on Light‐Activatable Dual Prodrug Nanoparticles for Effective Cancer Therapy. Advanced Healthcare Materials. 12(27). e2301133–e2301133. 10 indexed citations

Zhang, Guangcong, Xiang‐Nan Yu, Hongying Guo, et al.. (2023). PRP19 Enhances Esophageal Squamous Cell Carcinoma Progression by Reprogramming SREBF1-Dependent Fatty Acid Metabolism. Cancer Research. 83(4). 521–537. 20 indexed citations

Wang, Fu, Weiqi Xu, Wanqin Zhang, et al.. (2023). Transferrin receptor 1 promotes hepatocellular carcinoma progression and metastasis by activating the mTOR signaling pathway. Hepatology International. 18(2). 636–650. 7 indexed citations

Wang, Xiang, Jialei Sun, Guangcong Zhang, et al.. (2022). Iridium Complex-Loaded Sorafenib Nanocomposites for Synergistic Chemo-photodynamic Therapy of Hepatocellular Carcinoma. ACS Applied Materials & Interfaces. 14(33). 37356–37368. 20 indexed citations

Zhang, Guangcong, Ning‐Ping Zhang, Hai‐Ning Liu, et al.. (2022). microRNA-106b-5p Promotes Cell Growth and Sensitizes Chemosensitivity to Sorafenib by Targeting the BTG3/Bcl-xL/p27 Signaling Pathway in Hepatocellular Carcinoma. Journal of Oncology. 2022. 1–15. 9 indexed citations

10.

Du, Jun, Zhiyong Liu, Guangcong Zhang, et al.. (2022). Sorafenib-Loaded Cu2−xSe Nanoparticles Boost Photothermal–Synergistic Targeted Therapy against Hepatocellular Carcinoma. Nanomaterials. 12(18). 3191–3191. 12 indexed citations

11.

Wang, Fu, Jialei Sun, Guangcong Zhang, et al.. (2022). A novel murine model of combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Journal of Translational Medicine. 20(1). 579–579. 2 indexed citations

12.

Song, Guangqi, Haisi Dong, Danhui Ma, et al.. (2021). Tetrahedral Framework Nucleic Acid Delivered RNA Therapeutics Significantly Attenuate Pancreatic Cancer Progression via Inhibition of CTR1-Dependent Copper Absorption. ACS Applied Materials & Interfaces. 13(39). 46334–46342. 14 indexed citations

13.

Yu, Xiang‐Nan, Guangcong Zhang, Hai‐Ning Liu, et al.. (2021). Pre-mRNA processing factor 19 functions in DNA damage repair and radioresistance by modulating cyclin D1 in hepatocellular carcinoma. Molecular Therapy — Nucleic Acids. 27. 390–403. 9 indexed citations

14.

Dong, Haisi, Guangqi Song, Danhui Ma, et al.. (2021). Improved Antiviral Activity of Classical Swine Fever Virus-Targeted siRNA by Tetrahedral Framework Nucleic Acid-Enhanced Delivery. ACS Applied Materials & Interfaces. 13(25). 29416–29423. 13 indexed citations

15.

Sun, Jialei, Ning‐Ping Zhang, Guangcong Zhang, et al.. (2021). Tumor cell-imposed iron restriction drives immunosuppressive polarization of tumor-associated macrophages. Journal of Translational Medicine. 19(1). 347–347. 36 indexed citations

16.

Yu, Xiang‐Nan, Yong Deng, Guangcong Zhang, et al.. (2020). Sorafenib-Conjugated Zinc Phthalocyanine Based Nanocapsule for Trimodal Therapy in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. ACS Applied Materials & Interfaces. 12(15). 17193–17206. 37 indexed citations

17.

Yu, Xiang‐Nan, Guangcong Zhang, Jialei Sun, et al.. (2020). Enhanced mLST8 Expression Correlates with Tumor Progression in Hepatocellular Carcinoma. Annals of Surgical Oncology. 27(5). 1546–1557. 11 indexed citations

18.

Shi, Xuan, Taotao Liu, Xiang‐Nan Yu, et al.. (2020). microRNA-93-5p promotes hepatocellular carcinoma progression via a microRNA-93-5p/MAP3K2/c-Jun positive feedback circuit. Oncogene. 39(35). 5768–5781. 41 indexed citations

19.

Yu, Xiang‐Nan, Hongying Guo, Taotao Liu, et al.. (2019). Upregulated calcium‐binding tyrosine phosphorylation‐regulated protein‐a/b regulates cell proliferation and apoptosis and predicts poor prognosis in hepatocellular carcinoma. Journal of Cellular Biochemistry. 121(4). 2938–2949. 6 indexed citations

20.

Chen, Hong, Hairong Zhu, Xiang‐Nan Yu, et al.. (2019). <p>Overexpressed pepsinogen C is associated with poor prognosis in human hepatocellular carcinoma: a tissue microarray study</p>. Cancer Management and Research. Volume 11. 2927–2934. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liang Chu Breakdown of academic impact, for papers by Xiaotong Hu Breakdown of academic impact, for papers by Zhengxiang Zhang Breakdown of academic impact, for papers by Weizhong Tang Breakdown of academic impact, for papers by Yang Xu Breakdown of academic impact, for papers by Francisco Dası́ Breakdown of academic impact, for papers by Xinyu Huang